MAPT and Alzheimer disease: Emerging evidence suggests that these phytocannabinoids exert therapeutic-like effects on AD-related pathology, including Aβ accumulation and tau hyperphosphorylation (Coles et al., 2022; Barber et al., 2023; Libro et al., 2016).